Nu Holdings Ltd. (NU) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock m ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Avino Silver (ASM) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 13, 2025, might help the stock move higher if these key numbers are better than expecta ...

Under Armour (UAA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 13, 2025, might help the stock move higher if these key numbers are better than expecta ...

Core Viewpoint - Gladstone Investment (GAIN) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending March 2025, with the consensus outlook indicating a potential impact on its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to reveal quarterly earnings of $0.23 per share, reflecting a year-over-year decrease of 4.2%, while revenues are projected to be $24.78 million, an increase of 4.8% from the previous year [3]. - The consensus EPS estimate has been revised down by 1.43% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a negative Earnings ESP of -1.43%, suggesting that the Most Accurate Estimate is lower than the Zacks Consensus Estimate, complicating predictions of an earnings beat [11][10]. - The company currently holds a Zacks Rank of 3 (Hold), which further indicates uncertainty regarding the likelihood of surpassing the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Gladstone Investment was expected to post earnings of $0.24 per share but delivered only $0.23, resulting in a surprise of -4.17% [12]. - The company has not exceeded consensus EPS estimates in any of the last four quarters, highlighting a trend of underperformance [13]. Industry Comparison - In comparison, Morgan Stanley Direct Lending Fund (MSDL), another player in the Zacks Financial - SBIC & Commercial Industry, is expected to report earnings of $0.56 per share for the same quarter, reflecting a year-over-year decline of 11.1%, with revenues anticipated at $103.52 million, up 4.5% [17]. - Similar to Gladstone Investment, Morgan Stanley Direct Lending Fund has a negative Earnings ESP of -3.57% and a Zacks Rank of 3, making it difficult to predict an earnings beat [18].

The market expects 908 Devices Inc. (MASS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 13, 2025, might help the stock move higher if these key numbers ar ...

The market expects Ovid Therapeutics (OVID) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if t ...

The market expects On Holding (ONON) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 13, 2025, might help the stock move higher if these key numbers are bette ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Vivos Therapeutics, Inc. (VVOS) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the ...

Taysha Gene Therapies, Inc. (TSHA) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they ...

Core Insights - Avient reported revenue of $826.6 million for the quarter ended March 2025, a decrease of 0.3% year-over-year, with EPS remaining unchanged at $0.76 [1] - The revenue fell short of the Zacks Consensus Estimate of $833.46 million, resulting in a surprise of -0.82%, while the EPS exceeded the consensus estimate of $0.75 by 1.33% [1] Financial Performance Metrics - Specialty Engineered Materials sales were $308.40 million, below the average estimate of $312.56 million, reflecting a year-over-year decline of 1.9% [4] - Color, Additives and Inks sales reached $519.70 million, slightly below the average estimate of $521.10 million, with a year-over-year increase of 0.9% [4] - Corporate sales reported a loss of -$1.50 million, worse than the average estimate of -$0.80 million, marking a significant year-over-year change of +114.3% [4] Operating Income Analysis - Operating income for Color, Additives and Inks was $78.60 million, slightly above the average estimate of $78.01 million [4] - Operating income for Specialty Engineered Materials was $47.10 million, below the average estimate of $49.71 million [4] - Corporate operating loss was -$125 million, significantly worse than the average estimate of -$32.27 million [4] Stock Performance - Avient's shares have returned +13.9% over the past month, outperforming the Zacks S&P 500 composite's +11.5% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]